Yiqun Zhang

Yiqun Zhang

Auto-generated profile, based on publicly available information

Yiqun Zhang

Department of Vascular Neurosurgery, PLA Rocket Force Characteristic Medical Center, Beijing, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
SCShengsong Chen
Shengsong Chen
YZYiqun Zhang
Yiqun Zhang
TSTammy S. Santomango
Tammy S. Santomango
PWPhillip E. Williams
Phillip E. Williams
DLDana Borden Lacy
Dana Borden Lacy
OMOwen P. McGuinness
Owen P. McGuinness
Defects in insulin secretion and/or action contribute to the hyperglycemia of stressed and diabetic patients, and we hypothesize that failure to suppress glucagon also plays a role. We examined the chronic impact of glucagon on glucose uptake in chronically catheterized conscious depancreatized dogs placed on 5 days of nutritional support (NS). For 3 days of NS, a variable intraportal infusion of insulin was given to maintain isoglycemia (∼120 mg/dl). On day 3 of NS, animals received a constant low infusion of insulin (0.4 mU·kg−1·min−1) and either no glucagon (CONT), basal glucagon (0.7 ng·kg−1·min−1; BasG), or elevated glucagon (2.4 ng·kg−1·min−1; HiG) for the remaining 2 days. Glucose in NS was varied to maintain isoglycemia. An additional group (HiG + I) received elevated insulin (1 mU·kg−1·min−1) to maintain glucose requirements in the presence of elevated glucagon. On day 5 of NS, hepatic substrate balance was assessed. Insulin and glucagon levels were 10 ± 2, 9 ± 1, 7 ± 1, and 24 ± 4 μU/ml, and 24 ± 5, 39 ± 3, 80 ± 11, and 79 ± 5 pg/ml, CONT, BasG, HiG, and HiG + I, respectively. Glucagon infusion decreased the glucose requirements (9.3 ± 0.1, 4.6 ± 1.2, 0.9 ± 0.4, and 11.3 ± 1.0 mg·kg−1·min−1). Glucose uptake by both hepatic (5.1 ± 0.4, 1.7 ± 0.9, −1.0 ± 0.4, and 1.2 ± 0.4 mg·kg−1·min−1) and nonhepatic (4.2 ± 0.3, 2.9 ± 0.7, 1.9 ± 0.3, and 10.2 ± 1.0 mg·kg−1·min−1) tissues decreased. Additional insulin augmented nonhepatic glucose uptake and only partially improved hepatic glucose uptake. Thus, glucagon impaired glucose uptake by hepatic and nonhepatic tissues. Compensatory hyperinsulinemia restored nonhepatic glucose uptake and partially corrected hepatic metabolism. Thus, persistent inappropriate secretion of glucagon likely contributes to the insulin resistance and glucose intolerance observed in obese and diabetic individuals.

1 March 2003 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
CDChristine M. Donmoyer
Christine M. Donmoyer
SCShengsong Chen
Shengsong Chen
DLDana Borden Lacy
Dana Borden Lacy
DPDavid A. Pearson
David A. Pearson
APAdrian Poole
Adrian Poole
OMOwen P. McGuinness
Owen P. McGuinness
Total parenteral nutrition (TPN) markedly augments net hepatic glucose uptake (NHGU) and hepatic glycolysis in the presence of mild hyperglycemia and hyperinsulinemia. This increase is impaired by an infection. We determined whether the adaptation to TPN alters the responsiveness of the liver to insulin and whether infection impairs that response. Chronically catheterized dogs received TPN for 5 days. On day 3 of TPN, either a nonlethal hypermetabolic infection was induced (INF, n = 5) or a sham surgery was performed (SHAM, n = 5). Forty-two hours after clot implantation, somatostatin and glucagon (34 ± 3 vs. 84 ± 11 pg/ml in artery, SHAM vs. INF) were infused, and a three-step (120 min each) isoglycemic (∼120 mg/dl) hyperinsulinemic (∼12, 25, and 50 μU/ml) clamp was performed to simulate levels seen in normal, infected, and exogenous insulin treatment states. In SHAM, NHGU (3.5 ± 0.2 to 4.2 ± 0.4 to 4.6 ± 0.5 mg · kg−1· min−1) modestly increased. In INF, NHGU was consistently lower at each insulin step (1.1 ± 0.5 to 2.6 ± 0.5 to 2.8 ± 0.7 mg · kg−1· min−1). Although NHGU increased from the first to the second step in INF, it did not increase further with the highest dose of insulin. Despite increases in NHGU, net hepatic lactate release did not increase in SHAM and fell in INF. In summary, in the TPN-adapted state, liver glucose uptake is unresponsive to increases in insulin above the basal level. Although the infection-induced increase in insulin sustains NHGU, further increments in insulin enhance neither NHGU nor glycolysis.

1 September 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
HJHaifei Jiang
Haifei Jiang
YZYiqun Zhang
Yiqun Zhang
JPJiangxia Pang
Jiangxia Pang
HQHan-Cheng Qiu
Han-Cheng Qiu
ALAo-Fei Liu
Ao-Fei Liu
WJWei-Jian Jiang
Wei-Jian Jiang

1 September 2020 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
AZAi-Ping Zhang
Ai-Ping Zhang
YZYing-Ying Zhang
Ying-Ying Zhang
ALAo-Fei Liu
Ao-Fei Liu
KWKai Wang
Kai Wang
CLChen Li
Chen Li
WJWei-Jian Jiang
Wei-Jian Jiang

28 March 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
CLChen Li
Chen Li
JZJi Zhou
Ji Zhou
YZYi-Qun Zhang
Yi-Qun Zhang
JLJin Lv
Jin Lv
YZYing-Ying Zhang
Ying-Ying Zhang
WJWei-Jian Jiang
Wei-Jian Jiang
Objective: The aim of this study is to investigate the safety and efficiency of a Jrecan® flow restoration system, a novel thrombectomy device, in an arterial thromboembolic occlusion model of Beagle dogs.Methods: A total of 12 Beagle dogs with acute thromboembolism were randomized to receive mechanical thrombectomy with either Jrecan® flow restoration device or TrevoTM PROVUE Device (2:1). The efficacy and safety of the two devices, including recanalization rate, the presence of distal embolism, vasospasm, vessel perforation, and vessel injuries were evaluated through DSA and microscopic examination.Result: A 100% recanalization rate (mTICI 2b/3) was achieved in both groups. Endothelial and subendothelial injuries occurred in all target vessels. Focal disruption of internal elastic lamina was observed in 4 cases. The mean vessel injury score of the Jrecan® group was 1.16 ± 0.48, significantly lower than that of the TrevoTM group (1.54 ± 0.8) (P < 0.001).Conclusion: The Jrecan® and TrevoTM devices demonstrated an equally high recanalization rate in Beagle dogs with acute thromboembolism. However, histological findings revealed that the Jrecan® stent seemed to be safer than the TrevoTM device during clot retrieval, which might be related to a more appropriate radial force provided by the Jrecan® stent that resulted from its wider cell design.